Trial Information

Summary: A Study of Ocrelizumab Given as a Single or Dual Infusion in Patients With Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate

Status: Recruiting

Protocol Number: WA20496

Sponsor: Hoffmann-La Roche; Genentech Inc.

Company Division: Pharmaceutical

Official Scientific Title: A Randomised, Double-Blind study of the effect of Ocrelizumab Given as a Single Infusuion or a Dual Infusion Compared with Placebo on Signs and Symptoms in Patients with Active Rheumatoid Arthritis Who Have an Inadequate Response to methotrexate therapy

Brief Summary: This study will evaluate the efficacy and safety of ocrelizumab, compared to placebo, in patients with active rheumatoid arthritis who have an inadequate response to methotrexate therapy. Patients will be randomized 2:2:1 to receive 1)infusions of ocrelizumab 200mg iv on days 1 and 15, 2) infusions of ocrelizumab 400mg iv on day 1 and placebo iv on day 15, or 3)infusions of placebo iv on days 1 and 15. At the end of the placebo-controlled treatment period, patients in groups 1 and 3 will be re-randomized to receive either a single infusion of 400mg iv ocrelizumab or 2 infusions of 200mg iv ocrelizumab, and group 2 will receive a second single infusion of 400mg iv ocrelizumab. All patients will receive a stable dose of concomitant methotrexate (7.5-25mg/week)throughout the study. The anticipated time on study treatment is 1-2 years, and the target sample size is 100-500 individuas. In the US this trial is sponsored/managed by Genentech. Target sample size is 300.

Study Phase: III

Study Design / Study Details:

• Purpose: Treatment
• Allocation: Randomized
• Masking: Double Blind
• Control: Placebo
• Assignment: Parallel
• Endpoints: Safety/Efficacy

Study Type:

Condition: Rheumatoid Arthritis

Intervention Type: Drug

Intervention Name: ocrelizumab

Primary Outcome: 1. Percentage of patients with ACR20 response Time frame: Week 24

Key Secondary Outcomes: 1. ACR50, ACR70, DAS28, Eular response rate, SF-36, FACIT-Fatigue score, comparison of AE rates after single and dual infusions of ocrelizumab Time frame: Weeks 24 and 48 2. AEs and lab parameters; PK and PD parameters after single and dual infusions of ocrelizumab Time frame: Throughout study

Inclusion Criteria:

Exclusion Criteria:

Gender: Males or Females

Age Limits: Min: 18 Years

Accepts Healthy Volunteers: No

Anticipated Start Date: May, 2008

Trial Registration Date: 04/15/2008

Date Last Updated: 07/15/2008

Link To Trial Results

This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.

Trial listings updated: July 21, 2008 at 3:21:13 PM